On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

An article in The Journal For Nurse Practitioners found that Depo-Testosterone was the most cost-efficient TRT option, and ...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...

Netflix topped Wall Street expectations in the second quarter, boosted by strong subscriber growth, rising ad revenue, and hit content.

Chevron has won a major arbitration battle with Exxon Mobil, removing a key obstacle to its planned acquisition of Hess.

The post Enigmas Never Age appeared first on Reason.com.

The Enforcement Directorate has filed money laundering cases against AAP in three major scams—hospital construction, CCTV ...

In a busy week that includes much-anticipated quarterly reports, a pair of standouts among the finance and aerospace sectors ...